tradingkey.logo
tradingkey.logo
Search

Boehringer Ingelheim To Evaluate Combination Of Dll3‑Targeting T‑Cell Engager Plus Pd‑L1/Vegf‑A Bispecific Antibody In Small Cell Lung Cancer

ReutersApr 9, 2026 12:41 PM
facebooktwitterlinkedin

- BioNTech SE 22UAy.DE:

  • BOEHRINGER INGELHEIM: TO EVALUATE COMBINATION OF DLL3‑TARGETING T‑CELL ENGAGER PLUS PD‑L1/VEGF‑A BISPECIFIC ANTIBODY IN SMALL CELL LUNG CANCER

  • BOEHRINGER INGELHEIM: BIONTECH WILL SUPPLY PUMITAMIG AND CO WILL BE REGULATORY SPONSOR OF PHASE IB/II STUDY

  • BOEHRINGER INGELHEIM: BIONTECH AND CO RETAIN FULL RIGHTS TO THEIR RESPECTIVE ASSETS, AND AGREEMENT IS MUTUALLY NON-EXCLUSIVE

  • BOEHRINGER INGELHEIM: TRIAL WILL BEGIN DOSING PATIENTS IN SECOND HALF OF 2026

Further company coverage: [22UAy.DE]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI